Neon Therapeutics Inc (NASDAQ:NTGN)’s share price reached a new 52-week low during trading on Thursday . The company traded as low as $5.51 and last traded at $5.86, with a volume of 6649 shares traded. The stock had previously closed at $6.15.
A number of equities analysts have recently commented on the company. Zacks Investment Research raised Neon Therapeutics from a “hold” rating to a “buy” rating and set a $7.50 price target for the company in a report on Friday, November 16th. LADENBURG THALM/SH SH assumed coverage on Neon Therapeutics in a report on Monday, October 1st. They set a “buy” rating and a $20.00 price target for the company. Five analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $18.08.
Neon Therapeutics (NASDAQ:NTGN) last posted its quarterly earnings results on Monday, November 12th. The company reported ($0.67) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.12. Equities analysts anticipate that Neon Therapeutics Inc will post -5.17 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This news story was posted by Ticker Report and is owned by of Ticker Report. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.tickerreport.com/banking-finance/4001382/neon-therapeutics-ntgn-reaches-new-1-year-low-at-5-51.html.
About Neon Therapeutics (NASDAQ:NTGN)
Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.
Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.